It's Showtime for Optimer Pharmaceuticals
Optimer Pharmaceuticals (NAS: OPTR) is expected to report Q1 earnings around May 3. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Optimer Pharmaceuticals's revenues will expand 48.1% and EPS will remain in the red.
The average estimate for revenue is $21.3 million. On the bottom line, the average EPS estimate is -$0.46.
Last quarter, Optimer Pharmaceuticals booked revenue of $19.5 million. GAAP reported sales were 70% lower than the prior-year quarter's $64.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.02. GAAP EPS of $0.02 for Q4 were 93% lower than the prior-year quarter's $0.28 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 84.5%, 900 basis points worse than the prior-year quarter. Operating margin was -155.4%, much worse than the prior-year quarter. Net margin was 5.1%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $99.7 million. The average EPS estimate is -$1.83.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 106 members out of 146 rating the stock outperform, and 40 members rating it underperform. Among 45 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 30 give Optimer Pharmaceuticals a green thumbs-up, and 15 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Optimer Pharmaceuticals is outperform, with an average price target of $16.56.
- Add Optimer Pharmaceuticals to My Watchlist.
The article It's Showtime for Optimer Pharmaceuticals originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.